John D. Quisel - Dec 16, 2024 Form 4 Insider Report for Disc Medicine, Inc. (IRON)

Role
Chief Executive Officer, Director
Signature
By: /s/ Rahul Khara, as Attorney-in-Fact
Stock symbol
IRON
Transactions as of
Dec 16, 2024
Transactions value $
-$831,395
Form type
4
Date filed
12/18/2024, 07:41 PM
Previous filing
Jul 10, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRON Common Stock Options Exercise $12.9K +12.8K +17.75% $1.01 84.9K Dec 16, 2024 Direct F1
transaction IRON Common Stock Sale -$14.2K -219 -0.26% $64.66 84.6K Dec 16, 2024 Direct F1, F2
transaction IRON Common Stock Sale -$378K -5.77K -6.81% $65.58 78.9K Dec 16, 2024 Direct F1, F3
transaction IRON Common Stock Sale -$418K -6.31K -7.99% $66.35 72.6K Dec 16, 2024 Direct F1, F4
transaction IRON Common Stock Sale -$33.6K -500 -0.69% $67.20 72.1K Dec 16, 2024 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IRON Stock Option (Right to Buy) Options Exercise $0 -12.8K -5.37% $0.00 225K Dec 16, 2024 Common Stock 12.8K $1.01 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on July 2, 2024.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.04 to $65.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3), (4) and (5) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.04 to $66.03, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.04 to $67.01, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.04 to $67.54, inclusive.
F6 The shares underlying this option are fully vested and exercisable as of the date hereof.